Vaniprevir

Summary

Vaniprevir (CHEMBL4525964) is a phase-3 clinical-stage small-molecule hepatitis C protease inhibitor; indicated across 3 conditions including chronic hepatitis c virus infection and hepatitis c virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 11
• Chemistry: 757.9 Da · C38H55N5O9S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4525964
Name	Vaniprevir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	24765256
ChEBI	CHEBI:136047
Molecular formula	C38H55N5O9S
Molecular weight	757.9
InChIKey	KUQWGLQLLVFLSM-ONAXAZCASA-N

SMILES: CC[C@@H]1C[C@@]1(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C

IUPAC name: (1R,21S,24S)-21-tert-butyl-N-[(1R,2R)-1-(cyclopropylsulfonylcarbamoyl)-2-ethylcyclopropyl]-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6(11),7,9-triene-24-carboxamide

ChEBI definition: An azamacrocyclic compound that is a hepatitis C virus (HCV) NS3/4A protease inhibitor which is approved for the treatment of hepatitis C virus infections in Japan.

Pharmacological roles (ChEBI): hepatitis C protease inhibitor, antiviral drug.

Also known as: MK-7009, MK7009, Vaniprevir, vaniprevir, VANIPREVIR

Patent coverage: 175 distinct patent families (431 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 366 (85%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Thromboxane A2 receptor, Muscarinic acetylcholine receptor M1, Prostaglandin G/H synthase 1, Alpha-1A adrenergic receptor, Adenosine receptor A3, Vascular endothelial growth factor receptor 2, Cathepsin S.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
hepatitis C virus infection	2	MONDO:0005231	EFO:0003047

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1	4
PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01370642	PHASE3	COMPLETED	Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)
NCT01405560	PHASE3	COMPLETED	Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)
NCT01405937	PHASE3	COMPLETED	Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)
NCT00704184	PHASE2	COMPLETED	Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
NCT00704405	PHASE2	COMPLETED	Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)
NCT00880763	PHASE2	COMPLETED	A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)
NCT00895882	PHASE2	WITHDRAWN	Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)
NCT00518622	PHASE1	COMPLETED	Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)
NCT00954993	PHASE1	TERMINATED	Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)
NCT01010906	PHASE1	COMPLETED	A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)
NCT01678131	PHASE1	COMPLETED	Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).